Retatrutide, developed by Soma Corp., is receiving increasing attention as a potential treatment for obesity management . This dual-action medication integrates the activity of a GLP-1 receptor activator and a GIP receptor stimulant, aiming to simply promote weight loss but also address associated metabolic factors. Preliminary clinical trials have